Loading...
•
Jun 30, 2025
Pacira Q2 2025 Earnings Report
Pacira BioSciences reported its second quarter 2025 financial results, demonstrating solid execution across corporate, clinical, and commercial initiatives, with several key milestones advancing its 5x30 growth path.
Key Takeaways
Pacira BioSciences reported total revenues of $181.1 million for the second quarter of 2025, a slight increase from the previous year. The company experienced a net loss of $4.8 million, or $0.11 per share, but achieved a non-GAAP net income of $36.0 million, or $0.74 per diluted share. Key product sales showed growth for EXPAREL and ZILRETTA, while iovera° sales remained stable. The company also highlighted strategic advancements including a new revolving credit facility and expanded ZILRETTA promotional efforts.
Total revenues for Q2 2025 reached $181.1 million, showing a modest increase compared to Q2 2024.
The company reported a GAAP net loss of $4.8 million, or $0.11 per share, contrasting with a net income in the prior year, but achieved a non-GAAP net income of $36.0 million.
EXPAREL net product sales grew to $142.9 million, and ZILRETTA net product sales increased to $31.3 million, indicating continued market adoption for key products.
Pacira strengthened its financial flexibility with a new $300 million revolving credit facility and received a favorable court ruling yielding a $28.3 million payment from RDF.
Revenue by Segment
Forward Guidance
Pacira is updating its full-year 2025 total revenue and non-GAAP gross margin guidance, while reiterating its non-GAAP R&D expense, non-GAAP SG&A expense, and stock-based compensation guidance.
Positive Outlook
- Total revenue guidance is narrowed to a range of $730 million to $750 million, indicating more confidence in the forecast.
- Non-GAAP gross margin guidance is increased to 78% to 80%, suggesting improved cost efficiency and profitability.
- Reiteration of non-GAAP R&D expense guidance ($90 million to $105 million) provides stability in expected research investments.
- Reiteration of non-GAAP SG&A expense guidance ($290 million to $320 million) indicates controlled administrative and marketing costs.
- Stock-based compensation guidance of $56 million to $61 million remains consistent, offering clarity on equity-based compensation.
Challenges Ahead
- The narrowed total revenue range, while more precise, still represents a broad target.
- No specific negative forward guidance points were explicitly stated in the provided text beyond the general nature of guidance ranges.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...